☆ 3.8 Letter

Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review

BMJ MENTAL HEALTH (2023)

Related references

Note: Only part of the references are listed.
Review Psychiatry

The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis

Stefan Leucht et al.

Summary: This study aimed to compare the efficacy and side-effects of antipsychotic drugs in different subgroups of patients with schizophrenia. The findings suggest that the effects of antipsychotics in various patient subgroups were usually similar to those in the general population of patients with schizophrenia, but there is a lack of studies contributing to the subgroups, particularly in terms of side-effects.

LANCET PSYCHIATRY (2022)

Add to Collection
Review Psychiatry

Systematic Review of Blinding Assessment in Randomized Controlled Trials in Schizophrenia and Affective Disorders 2000-2010

Christopher Baethge et al.

PSYCHOTHERAPY AND PSYCHOSOMATICS (2013)

Add to Collection
Article Psychiatry

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

Mark S. George et al.

SCHIZOPHRENIA RESEARCH (2007)

Add to Collection
Article Public, Environmental & Occupational Health

Blinded trials taken to the test:: an analysis of randomized clinical trials that report tests for the success of blinding

A. Hrobjartsson et al.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2007)

Add to Collection
Article Medicine, General & Internal

Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials

D Fergusson et al.

BRITISH MEDICAL JOURNAL (2004)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.